Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 3;9(1):1746172.
doi: 10.1080/2162402X.2020.1746172.

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Bryan Oronsky  1 , Corey A Carter  1 , Scott Caroen  1 , Curtis Scribner  1 , Arnold Oronsky  2 , Tony R Reid  1
Affiliations

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

Bryan Oronsky et al. Oncoimmunology. .

Abstract

The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.

Keywords: CD47; Immunotherapy; MYC; erythrophagoimmunotherapeutic; hemoglobin; small molecule; tumor associated macrophage.

PubMed Disclaimer

References

    1. Oronsky B, Scicinski J, Cabrales P, Minchinton A.. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clin Epigenetics. 2016. May 11;8:53. doi: 10.1186/s13148-016-0220-7. - DOI - PMC - PubMed
    1. Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL.. Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget. 2017. June 12;8(60):102511–2. doi: 10.18632/oncotarget.18455. - DOI - PMC - PubMed
    1. Oronsky B, Scribner C, Aggarwal R, Cabrales P. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. J Cancer Res Clin Oncol. 2019. August;145(8):2045–2050. doi: 10.1007/s00432-019-02958-4. - DOI - PMC - PubMed
    1. Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics. 2017. January 19;9:4. doi: 10.1186/s13148-017-0312-z. - DOI - PMC - PubMed
    1. Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G. NO to cancer: the complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 2015. December;6:1–8. doi: 10.1016/j.redox.2015.07.002. - DOI - PMC - PubMed